Clinical Trial

EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

Study acronym: ERIS
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the optimal sequence of EGFR-inhibitors in lung cancer patients with EGFR-positive tumors not amenable for curative treatment. Life quality, adverse effects and tumor response will be evaluated and analyses of obtained blood and tumor samples will be performed to identify molecular profiles and biomarkers that can be used for treatment decisions.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-06-26.
Trial Details
NCT Number NCT06486142
Lead Sponsor Region Skane
Collaborators: Swedish Lung Cancer Study Group
Conditions Non-Small Cell Lung Cancer
Enrollment 200 participants
Start Date 2022-09-21
Primary Completion 2028-09 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-14